<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641067</url>
  </required_header>
  <id_info>
    <org_study_id>1439-051</org_study_id>
    <nct_id>NCT02641067</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Pharmacokinetics of Doravirine in Participants With Severe Renal Impairment (MK-1439-051)</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-1439 (Doravirine) in Subjects With Severe Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of severe renal impairment on the pharmacokinetics of
      doravirine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 26, 2016</start_date>
  <completion_date type="Actual">May 25, 2016</completion_date>
  <primary_completion_date type="Actual">May 14, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration versus time curve (AUC) of doravirine from 0 to infinity (AUC 0-∞)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose; and 96 hours post-dose for severe renal impairment only</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma drug concentration of doravirine at 24 hours postdose (C24)</measure>
    <time_frame>24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of doravirine</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 12, 24, 48, 72 hours post-dose; and 96 hours post-dose for severe renal impairment only</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe renal impairment receive a single oral dose of 100 mg doravirine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Matched Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally</description>
    <arm_group_label>Severe Renal Impairment</arm_group_label>
    <arm_group_label>Healthy Matched Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants with renal impairment:

          -  is a non-smoker or moderate smoker

          -  has a body mass index (BMI) ≥ 18.5 and ≤ 40.0 kg/m^2

          -  other than renal impairment, participant is judged to be in good health based on
             medical history, physical examination, vital signs, and laboratory safety tests

          -  female informed of the risks of pregnancy, agree not to become pregnant while
             participating in this study. Female of childbearing potential must either be sexually
             inactive for 14 days prior to dosing and throughout the study, or uses one acceptable
             birth control method

          -  female of non-childbearing potential must have undergone sterilization procedures at
             least 6 months prior to dosing.

          -  has baseline estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m^2

        Exclusion Criteria:

        Participants with renal impairment:

          -  is mentally or legally incapacitated or has significant emotional problems

          -  has a history or presence of clinically significant medical or psychiatric condition
             or disease

          -  has history or presence of alcoholism or drug abuse within the past 2 years

          -  has history or presence of hypersensitivity or idiosyncratic reaction to the study
             drug, any inactive ingredients, or related compounds

          -  has history or presence of renal artery stenosis

          -  has had a renal transplant or nephrectomy

          -  has rapidly fluctuating renal function as determined by historical measurements

          -  female is pregnant or lactating

          -  has positive results for the urine or saliva drug and urine or breath alcohol screen
             at screening or check-in

          -  has positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or hepatitis C virus (HCV)

          -  is unable to refrain from or anticipates the use of any drug, including prescription
             and non-prescription medications, herbal remedies, or vitamin supplements beginning 14
             days prior to dosing and throughout the study. Certain medications including those to
             treat kidney disease will be permitted. Other medications may be permitted following
             consultation with the Sponsor Clinical Monitor.

          -  is unable to refrain from or anticipates the use of inducers of cytochrome P450 3A
             (CYP3A) or permeability glycoprotein (P-gp) transporters for at least 28 days prior to
             dosing and throughout the study.

          -  has been on a diet incompatible with the on-study diet, within 28 days prior to
             dosing, and throughout the study

          -  has donated blood or had significant blood loss within 56 days prior to dosing

          -  has donated plasma within 7 days prior to dosing

          -  has participated in another clinical trial within 28 days prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

